Business Context and Reporting Period
Company: Novavax, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: July 6, 2022
Event: Entry into a Material Definitive Agreement (Modification No. 14 to Project Agreement No. 01).
Key Financial Metrics
This filing is a current report regarding a contractual agreement and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Agreement Details
On July 6, 2022, Novavax entered into Modification No. 14 to its Project Agreement with Advanced Technology International (acting for the Medical CBRN Defense Consortium/Operation Warp Speed). Key terms include:
- Initial Delivery: Approximately 3 million doses of the NVX-CoV2373 vaccine candidate to the United States Government (USG).
- Manufacturer: Serum Institute of India Private Limited or another FDA-approved location.
- Contingencies: Delivery is contingent upon FDA Emergency Use Authorization (EUA) approval, label language/artwork approvals, and CDC Advisory Committee on Immunization Practices recommendations.
- Additional Supply: Potential for up to 100 million total doses (inclusive of the initial 3 million) dependent on USG demand, FDA strain selection guidance, and price agreement.
Guidance, Outlook, and Risks
Outlook: The agreement establishes a framework for potential large-scale supply (up to 100 million doses) pending regulatory milestones and demand.
Risks and Contingencies:
- Execution of the initial 3 million dose delivery is strictly contingent on FDA EUA approval and CDC recommendations.
- Additional deliveries beyond the initial lot depend on USG demand and future price negotiations.
- The full text of the Modification will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2022.
Investor Verification Checklist
- Verify the status of FDA Emergency Use Authorization (EUA) for NVX-CoV2373.
- Confirm CDC Advisory Committee on Immunization Practices recommendations regarding the vaccine.
- Monitor the upcoming Form 10-Q (Q3 2022) for the full text of Modification No. 14.
- Assess USG demand signals and potential pricing agreements for the additional 97 million doses.